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Background/Introduction
Endomyocardial biopsy (EMB) is widely used for routine
surveillance of cardiac allograft rejection. The need for
continued EMB beyond the first year after cardiac trans-
plantation is controversial.
Aims/Objectives
The aim of this study was to investigate the use of EMB in
monitoring long term surviving heart transplant recipients.
Method
We conducted a retrospective chart review of all
patients at our center 2 years or more after heart trans-
plantation. 154 HTx patients between 2000-2012 were
included in this study. Significant cellular rejection was
defined as grade 2R or 3R using ISHLT nomenclature.
Patients were analyzed assessing immunosuppressive
regimen and procedural related complications.
Results
Of 154 cardiac transplant patients, 110 (71.4%) had a fol-
low-up of more than 2 years. Interestingly, 17 of these
long-term survivors of cardiac transplantation developed
at least 1 episode of significant late (>2 years after Tx)
cellular rejection (15.5%). Analyzing the respective
immunosuppressive regimen showed increased number
of calcineurin inhibitor (CNI)-free regimen (64.7%) in
patients rejecting late after heart transplantation. The
overall incidence of procedural related complications was
low (1.0%) and none was life-threatening.
Discussion/Conclusion
The above data demonstrates that endomyocardial biop-
sies continue to detect clinically significant rejection
beyond 2 years after cardiac transplantation. Late rejec-
tion was not depending on previous episodes of early
cellular rejections. Therefore, we recommend long-term
routine endomyocardial biopsies in cardiac transplant
recipients especially in patients at high risk due to the
immunosuppressive regimen.
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